|Awarded On||August 24, 2018|
|Title||Fluorescently Labeled Somatostatin Analogs for Image-Guided Surgery in Neuroendocrine Tumors|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Ali Azhdarinia|
|Cancer Sites||Lung and Bronchus, Pancreas, Small Intestine|
Cancer surgery is the foundation for curative therapy and has major therapeutic implications for patients with neuroendocrine tumors (NETs). Unlike most cancers, surgery is performed in NETs even if metastases are present in order to control excessive hormone production that could further stimulate tumor growth. In NETs, surgery is often complicated by difficulties in identifying small liver metastases, which give rise to remarkably high recurrence rates. Accordingly, the goal of this project is to develop a contrast agent that improves intraoperative detection of NETs and increases overall survival. Radiolabeled peptides are widely used in the clinic for NET imaging before and after surgery...